Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Transparent Process
Open Access

Oxidised metabolites of the omega-6 fatty acid linoleic acid activate dFOXO

View ORCID ProfileSo Yeon Kwon, Karen Massey, View ORCID ProfileMark A Watson, Tayab Hussain, View ORCID ProfileGiacomo Volpe, View ORCID ProfileChristopher D Buckley, View ORCID ProfileAnna Nicolaou, View ORCID ProfilePaul Badenhorst  Correspondence email
So Yeon Kwon
1Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for So Yeon Kwon
Karen Massey
2Bradford School of Pharmacy, University of Bradford, Bradford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A Watson
1Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark A Watson
Tayab Hussain
1Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giacomo Volpe
1Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Giacomo Volpe
Christopher D Buckley
3Institute of Inflammation and Ageing, Centre for Translational Inflammation Research, Queen Elizabeth Hospital, Edgbaston, UK
4Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher D Buckley
Anna Nicolaou
2Bradford School of Pharmacy, University of Bradford, Bradford, UK
5Laboratory for Lipidomics and Lipid Biology, Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, Manchester, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Nicolaou
Paul Badenhorst
1Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Badenhorst
  • For correspondence: p.w.badenhorst@bham.ac.uk
Published 28 January 2020. DOI: 10.26508/lsa.201900356
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Immunomodulatory effects of PUFAs on Drosophila inflammatory tumours.

    (A) Inflammatory melanotic tumour model relies on temperature conditional activation of JAK/STAT in hopTum gain-of-function heterozygous females. (B) Melanotic tumour indicated (dashed circle). Dissected melanotic tumour from hopTum female carrying the lamellocyte marker (MSNF9-mCherry [Tokusumi et al, 2009a, 2009b]) reveals melanotic tumour is composed of lamellocyte aggregates. (C) Real-time RT-PCR was used to determine levels of inflammation markers in control and hopTum larvae raised in both standard media and media supplemented with 9-(S)-HODE (1 μM). RpL32 provided an endogenous control to normalise expression. (D, E, F) Melanotic tumour incidence was assayed in hopTum heterozygous females raised on standard medium supplemented with fatty acids. (D) SFA supplementation (coconut oil) did not increase tumour incidence. (E) Omega-6 PUFA linoleic acid (LA) supplementation increased tumour incidence. (F) Omega-3 PUFA (α-linoleic acid [ALA]) supplementation suppressed melanotic tumours even when 0.15% of LA was present. Cultures were incubated at 27°C except for omega-6 PUFA, which was conducted at both 25°C and 27°C. As hopTum is temperature-sensitive-conditional, changes in culture temperatures modify basal melanotic tumour incidence, allowing better resolution of either suppressors or enhancers of inflammation (Badenhorst et al, 2002). (G) Schematic showing biosynthetic pathways of omega-6 PUFA derived lipid mediators. The 18-carbon (C18) omega-6 PUFA LA can be converted to arachidonic acid, the precursor of eicosanoids, a family of potent bioactive lipids that include the cyclooxygenase (COX)-derived prostaglandins. (H, I) hopTum larvae were raised on media supplemented with 0.15% LA and the lipid extract was analysed by LC-MS/MS for the presence of PGF2α, PGE2, and PGD2. (H, I) Neither PGF2α (multiple reaction monitoring [MRM]: m/z: m/z 353>309, 353>247 and 353>193) nor (I) PGE2 and PGD2 (MRM: m/z 351>315, 351>271, and 351>333) were detected in Drosophila lipid extracts. Data information: in (D, E, F), 10 replicate crosses were used for each assay point. Box and whiskers plots were generated using R. * indicates values statistically significantly different from unsupplemented, P-value < 0.001 determined using t test. NS indicates not statistically significantly different.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Drosophila lack prostaglandins.

    (A, B) LC-MS/MS spectra for analyses to detect (A) PGF2α and (B) PGE2 and PGD2. hopTum larvae were raised on normal media (control) and media supplemented with either 0.15% LA (Omega-6) or 0.15% ALA (Omega-3). Molecular ions used were as follows: m/z 353>309, 353>193, and 353>247 for PGF2α and m/z 351>315, 351>271, and 351>333 for PGE2 and PGD2.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. Drosophila produce the lipid mediator 9-HODE which is required for inflammatory responses.

    Omega-6 PUFA LA can be processed either by COX, lipoxygenase, or myeloperoxidase (MPO) enzymes to produce hydroxy-octadecadienoic acids (HODEs). (A, B) 9-HODE (MRM m/z 295>171) and (B) 13-HODE (MRM m/z 295>195) were identified in Drosophila lipid extracts. (C) The concentrations of 9-HODE and 13-HODE were unaltered after ALA (omega-3 PUFA) supplementation but increased after LA supplementation (omega-6 PUFA). Data are mean and SD of three independent determinations. (D) Chiral LC-MS/MS shows that 9-(S)-HODE was the predominant species on non-supplemented (NS) and ALA supplemented medium, whereas LA supplementation promoted the production of both 9- and 13-HODE, at (R) and (S) configuration. (E) 9-(S)-HODE (1 μM) supplementation increased melanotic tumour incidence in hopTum heterozygous females and increased lethality of hopTum heterozygous males. (F) Purified Pxt exhibited MPO activity in vitro. 3xFLAG-tagged Pxt haem peroxidase domain was over-expressed in HeLa cells, purified, and assayed for MPO activity. MPO Inhibitor-1 was used to inhibit peroxidase activity. (G) Reduction in levels of Pxt using Pxtf05258 and PxtEY03052 suppressed melanotic tumours. (H) MPO inhibitors suppressed melanotic tumours, IC50 of MPO inhibitor-1 is indicated. For (G, H), tumour incidence was assayed in heterozygous COX/MPO mutant/hopTum females raised at 27°C on medium supplemented with 0.15% LA. (I) Increased melanotic tumour incidence in hopTum heterozygous females raised on 9(S)-HODE-containing media (1 μM) was not suppressed by reduction in Pxt levels using Pxtf05258. Data information: in (C, D), three replicates were used for each assay point. * indicates values statistically significantly different from control, P-value < 0.05 determined using t test. In (E, F, G, H, I) 10 replicate crosses were used for each assay point. Box and whiskers plots were generated using R. * indicates values statistically significantly different from unsupplemented, P-value < 0.001 determined using t test. NS indicates not statistically significantly different.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Pxt is required for inflammatory responses.

    (A, B, C) Pxtf05258 homozygous mutants show reduced lifespan relative to control flies (A) under control laboratory conditions, (B) after sterile wounding and (C) in response to fungal. Data information: mean survival in (A, B, C) was calculated from five cohorts of 50 flies per genotype/condition assayed every 24 h.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Transcriptome analysis reveals 9-(S)-HODE regulates dFOXO targets.

    (A) Heat map showing differentially expressed genes in S2 cells 12 and 24 h after 9-(S)-HODE treatment. Scale bar indicates fold-change relative to mock-treated control. (B) Gene ontology (GO) network analysis of the 325 genes significantly up-regulated in S2 cells 24 h after 9-(S)-HODE treatment. (C) GO network analysis of the 224 genes significantly down-regulated in S2 cells 24 h after 9-(S)-HODE treatment. (D, E) iRegulon analysis of up- and down-regulated genes defines TF regulatory circuits that transduce 9-(S)-HODE signals. Binding sites for dFOXO are a common feature of both sample sets. (F) Heat map showing fold-change in transcript levels of known dFOXO target genes after 9-(S)-HODE treatment. (G) Venn diagram showing overlap between 9-(S)-HODE transcriptional targets and genes previously defined as dFOXO targets by chromatin immunoprecipitation (ChIP) on chip analysis (Spellberg dFOXO ChIP). Hypergeometric test was performed in R to determine significance of overlap.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. 9-(S)-HODE differentially regulated networks.

    (A) GO classification of 9-(S)-HODE–regulated genes. (B) Network analysis of differentially expressed genes using known Drosophila protein–protein and genetic interactions (BioGRID) or GO annotations.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. 9-(S)-HODE activates dFOXO.

    (A) 9-(S)-HODE (10 μM) treatment inhibits Drosophila S2 cell proliferation. (B) FACS cell cycle analysis confirms cell cycle arrest. G1 and G2/M peaks seen in mock-treated S2 cells were absent in 9-(S)-HODE–treated cells replaced by a broad sub-G1 peak. (C) Western analysis of dFOXO levels in S2 cells 24 h after 9-(S)-HODE treatment. MAb E7 anti-tubulin was used as a loading control. (D) Immunofluorescence microscopy of Drosophila S2 cells shows elevated levels of nuclear dFOXO after 9-(S)-HODE treatment. (E) Quantitation of nuclear dFOXO signals in S2 cells after mock or 9-(S) HODE treatment. (F) Live imaging of 9-(S)-HODE–treated dFOXO-mCherry fat body confirming 9-(S)-HODE elevates nuclear dFOXO within 10 min of treatment. (G) Ratio of dFOXO ChIP signal at known dFOXO targets and control genomic regions in S2 cells treated with 9-(S)-HODE for 24 h relative to mock/untreated dFOXO ChIP signal. (H) Immunofluorescence microscopy of Drosophila S2 cells reveals elevated levels of nuclear dFOXO after 9-(S)-HODE treatment is resistant to insulin treatment. (I) Quantitation of nuclear dFOXO signals in mock or 9-(S) HODE treated S2 cells that are subsequently treated with insulin for 90 min before fixation. (J) 9-(S)-HODE treatment of human HeLa cells triggers nuclear entry of transiently transfected FOXO3-HA. (K) 9-(S)-HODE treatment of FOXO3-HA transfected human HeLa cells activates transcription from the FOXO3a reporter plasmid FHRE-luc. Data information: in all panels, * indicates values statistically significantly difference P-value < 0.001 determined using t test. NS, no significant difference. In (E, K), 50 determinations were used for each assay point. Box and whiskers plots were generated using R. In (G, I), three replicates were used for each assay point.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. 13-(S)-HODE does not activate dFOXO.

    (A) Unlike 9-(S)-HODE, 13-(S)-HODE failed to induce dFOXO nuclear localisation. (B) Quantitation of dFOXO-mCherry nuclear signal. Images were collected at identical scan settings and at least 10 replicates used per data point. Data information: in (B, C, D), 50 determinations were used for each assay point. Box and whiskers plots were generated using R. * indicates values statistically significantly different from unsupplemented, P-value < 0.001 determined using t test. NS, no significant difference.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Control of dFOXO by 9-HODE is mediated via the JNK pathway.

    (A) Tumour incidence in heterozygous hopTum females flies was decreased by reduction in dFOXO (FoxoΔ94) or Bsk (bsk1) levels but increased by removal of Puc (pucE69). (B) JNK activation was confirmed by Western analysis of human HeLa and Drosophila S2 cells 24 h after 9-(S)-HODE treatment using anti-pJNK antibodies. MAb E7 anti-tubulin is used as a loading control. Expected pJNK (p54 and p56) species in S2 extracts are indicated. (C) Quantitation of pJNK levels in 9-(S)-HODE–treated cells relative to mock-treated control. (D) Confocal immunofluorescence microscopy of mock and 9-(S)-HODE–treated S2 cells using anti-pJNK anti-dFOXO antibodies confirms JNK activation after 9-(S)-HODE treatment. (E) Quantitation of pJNK signals in S2 cells. (F) Fat body–specific over-expression of dominant-negative Bsk variants or RNAi-mediated inhibition bsk reduces 9-(S)-HODE stimulated dFOXO-mCherry nuclear entry. (G) Quantitation of dFOXO-mCherry nuclear signal in fat body tissue. (H) Pretreatment with JNK inhibitor SP600125 prevents nuclear dFOXO localisation after 9-(S)-HODE treatment. (I) Quantitation of dFOXO nuclear signal in S2 cells after treatment with 9-(S) HODE alone or with the JNK inhibitor SP600125. (J) 9-(S) HODE treatment of S2 cells does not increase reactive oxygen species as revealed by CellROX staining. (K) Reactive oxygen species are not required for 9-(S)-HODE–triggered dFOXO nuclear localisation as simultaneous treatment with N-acetyl-L-cysteine (NAC) does not prevent nuclear entry. (L) Proposed model indicating how 9-HODE activation of FOXO could confer insulin resistance. Data information: in (A), 10 replicate crosses were used for each assay point. Box and whiskers plots were generated using R. * indicates values statistically significantly different from unsupplemented, P-value < 0.001. In (E, G, I, K), 50 determinations were used for each assay point. Box and whiskers plots were generated using R. * indicates values statistically significantly different from unsupplemented, P-value < 0.001 determined using t test.

Tables

  • Figures
  • Supplementary Materials
  • Key Resources Table.

    Reagent or resourceSourceIdentifier
    Antibodies
    Mouse anti-B-tubulin MAb E7Developmental Studies Hybridoma BankRRID:AB_528499
    Mouse anti-phospho-SAPK/JNK (Thr183/Tyr185) MAb G9Cell Signalling TechnologyRRID:AB_2307321
    Rabbit anti-dFOXOMichael MarrBRD10
    Cy3-conjugated AffiniPure goat anti-rabbit antibodyJackson ImmunoResearchCat. no. 111-167-003
    FITC-conjugated AffiniPure donkey anti-mouse antibodyJackson ImmunoResearchCat. no. 715-095-151
    Anti-rabbit HRP-conjugated IgG (H+L)GE Healthcare
    Anti-mouse HRP-conjugated IgG (H+L)GE Healthcare
    Rat monoclonal anti-HA-tag [7C9]ChromoTek
    Deposited data
    Agilent microarray dataThis articleArray express: E-MTAB-6253
    Experimental models: organisms/strains
    Drosophila melanogaster: Schneider 2, CVCL_Z232InvitrogenRRID: CVCL_Z232
    Homo sapiens: HeLa CCL-2American Type Culture Collection (ATCC)RRID: CVCL_0030
    D. melanogaster: hopTumBloomington Drosophila Stock CenterRRID: BDSC_8492
    D. melanogaster: w1118Bloomington Drosophila Stock CenterRRID: BDSC_5905
    D. melanogaster: w1118; foxoΔ94/TM6B, Tb1Bloomington Drosophila Stock CenterRRID: BDSC_42220
    D. melanogaster: w1118 P{w+mC=UAS-bsk.DN}2Bloomington Drosophila Stock CenterRRID: BDSC_6409
    D. melanogaster: bsk1 cn1 bw1 sp1/CyO,Bloomington Drosophila Stock CenterRRID: BDSC_3088
    D. melanogaster: w*; cno3 P{ry+t7.2=A92}pucE69/TM6B, P{w+mC=iab-2(1.7)lacZ}6B, Tb1Bloomington Drosophila Stock CenterRRID: DGGR_109029
    D. melanogaster: w1118; P{GD10555}v3413 UAS-bskRNAiBloomington Drosophila Stock CenterRRID:FlyBase_FBst0460476
    D. melanogaster: w1118; P{GAL4}fat (FB-GAL4)Gronke et al (2003)RRID:FlyBase_FBti0013267
    D. melanogaster: w1118; P{GD10555}v3413 UAS-bskRNAiBloomington Drosophila Stock CenterRRID:FlyBase_FBst0460476
    D. melanogaster: y1 w67c23; P{EPgy2}PxtEY03052Bloomington Drosophila Stock CenterRRID:BDSC_15620
    D. melanogaster: PBac{WH}Pxtf05258The Exelixis Collection at the Harvard Medical SchoolRRID: FBti0067872
    D. melanogaster: dfoxo-v3-mCherryKakanj et al (2016)N/A
    Beauveria bassiana CABI(T. Petch, 1947) IMI: 12942
    Oligonucleotides
    foxo-ChIP-control forward primer (5′-AGCCCGCGAAGATACAAGAG-3′)This articleN/A
    foxo-ChIP-control reverse primer (5′-AGCCACAAACAGCGACAGAA-3′)This articleN/A
    pdcd4-ChIP forward primer (5′-CCGTTGGGAGTCTCTCTCTC-3′)This articleN/A
    pdcd4-ChIP reverse primer (5′-GCTCTCCCCACCTTCTCACC-3′)This articleN/A
    hsp26-ChIP forward primer (5′-GTGCGCCTGTATGAGTGAGA-3′)This articleN/A
    hsp26-ChIP reverse primer (5′-GTGGGAGATTGCTGGCGTTA-3′)This articleN/A
    4EBP-ChIP forward primer (5′-CAAGAACCAGCCGGTTTGTC-3′)This articleN/A
    4EBP-ChIP reverse primer (5′-GCTCTCTTCTCGCTCTTTCG-3′)This articleN/A
    Pxt-RT-PCR forward primer (5′-GCAGCTCCTCGATGTGATTGAAAC-3′)This articleN/A
    Pxt-RT-PCR reverse primer (5′-CTAGAGTGCGAGCGAGAGGTAAGA-3′)This articleN/A
    RpL32-RT-PCR forward primer (5′-ATCCGCCACCAGTCGCATCGATATGCTAAG-3′)This articleN/A
    RpL32-RT-PCR reverse primer (5′-TCTTGAGAACGCAGGCGACCGTTGGGGTTG-3′)This articleN/A
    DptA-RT-PCR forward primer (5′-GCAGTTCACCATTGCCGTCGCCTTACTTTG-3′)This articleN/A
    DptA-RT-PCR reverse primer (5′-TGAAGATTGAGTGGGTACTGCGGTGGTGGA-3′)This articleN/A
    Drs-RT-PCR forward primer (5′-ATCAAGTACTTGTTCGCCCTCTTCGCTGTC-3′)This articleN/A
    Drs-RT-PCR reverse primer (5′-CTCGTTGTCCCAGACGGCACAGGGACCCTT-3′)This articleN/A
    Recombinant DNA
    Plasmid: pTRE3GClontech631173
    pTRE3G-3XFLAGThis articleN/A
    pTRE3G-3XFLAG-PxnThis articleN/A
    Software and algorithms
    FIJISchindelin et al (2012)https://imagej.net/Fiji
    MarrayPaquet (2009)https://bioconductor.org/packages/release/bioc/html/marray.html
    LimmaRitchie et al (2015)http://bioconductor.org/packages/release/bioc/html/limma.html
    Bioconductor version 3.4http://bioconductor.orghttps://bioconductor.org/news/bioc_3_4_release/
    R version 3.1.2https://www.R-project.orghttps://cran.r-project.org/bin/windows/base/old/3.1.2/
    ClueGo(Bindea et al, 2009)https://apps.cytoscape.org/apps/cluego
    esyN(Bean et al, 2014)http://www.esyn.org
    Cytoscape(Shannon et al, 2003)https://cytoscape.org
    iRegulon(Janky et al, 2014)http://iregulon.aertslab.org

Supplementary Materials

  • Figures
  • Tables
  • Table S1 Fatty acid analysis of Drosophila third instar larvae lipid extract.

  • Supplemental Data 1.

    Gene with most significant changes in expression following 12 h 9-(S)-HODE treatment.[LSA-2019-00356_Supplemental_Data_1.xlsx]

  • Supplemental Data 2.

    Gene with most significant changes in expression following 24 h 9-(S)-HODE treatment.[LSA-2019-00356_Supplemental_Data_2.xlsx]

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Oxidised metabolites of the omega-6 fatty acid linoleic acid activate dFOXO
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Omega-6 PUFA metabolites activate dFOXO
So Yeon Kwon, Karen Massey, Mark A Watson, Tayab Hussain, Giacomo Volpe, Christopher D Buckley, Anna Nicolaou, Paul Badenhorst
Life Science Alliance Jan 2020, 3 (2) e201900356; DOI: 10.26508/lsa.201900356

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Omega-6 PUFA metabolites activate dFOXO
So Yeon Kwon, Karen Massey, Mark A Watson, Tayab Hussain, Giacomo Volpe, Christopher D Buckley, Anna Nicolaou, Paul Badenhorst
Life Science Alliance Jan 2020, 3 (2) e201900356; DOI: 10.26508/lsa.201900356
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 3, No. 2
February 2020
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Data Availability
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Cell Biology
  • Genomics & Functional Genomics
  • Immunology

Related Articles

  • No related articles found.

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • NLRP3 controls ATM activation
  • RIF1 stabilizes replication domains
  • Chromatin context-dependent interferon response
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.